Impactos negativos da administração de hidroxicloroquina e anticoagulante em pacientes com infecção por SARS-COV-2: um ensaio clínico randomizado
DOI:
https://doi.org/10.11606/issn.1679-9836.v101i4e-187545Palavras-chave:
COVID-19, SARS-CoV-2, Prevenção de acidentes., ComplicaçõesResumo
Objetivo: Avaliar antimalárico com ou sem tratamento anticoagulante, em pacientes com infecção recente por SARS-COV-2. Métodos: Estudo clínico realizado no Hospital das Clínicas Samuel Libânio da Universidade do Vale do Sapucaí, Pouso Alegre-MG. Aprovado pelo Comitê de Ética (4.034.077) e registrado nos Ensaios Clínicos (NCT04788355). Pacientes suspeitos de COVID-19 foram incluídos na sala de emergência. Os grupos foram: C (controle) com 6 pacientes, A (anticoagulante apixabana) com 9 pacientes, H (hidroxicloroquina) com 5 pacientes e HA (hidroxicloroquina e anticoagulante apixabana) com 8 pacientes. Resultados: não houve diferenças significativas entre os grupos. O grupo HA, no qual houve intervenção com dois medicamentos, apresentou maior número de dias com sintomas (p = 0,037) e piores resultados, quando comparado ao controle: os sintomas mais relevantes foram: tosse (p = 0,001), e anosmia/ageusia (p = 0,011) cefaléia (p = 0,001). Conclusão: O presente estudo teve início quando havia dúvidas sobre o uso de medicamentos como hidroxicloroquina (HCQ) e apixabana (APX). O “n” reduzido foi definido por meio de questões burocráticas e polêmicas independentes das ações dos autores. Nenhum benefício clínico foi associado com HCQ e APX. Houve um aumento no número de dias sintomáticos quando HCQ e APX foram administrados. Apesar das limitações, não houve indicação terapêutica dos medicamentos avaliados.
Downloads
Referências
Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020;13(11):1601-1610. doi: https://doi.org/10.1016/j.jiph.2020.07.011
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020 Apr; 76:71-76. Epub 2020 Feb 26. Erratum in: Int J Surg. 2020;77:217. doi: https://doi.org/10.1016/j.ijsu.2020.02.034
Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966 Jan 8; 1(7428):76-7. doi: https://doi.org/10.1016/s0140-6736(66)92364-6
Nascimento VA, Corado ALG, Nascimento FO, Costa AKA, Duarte DCG, Luz SLB. Genomic and phylogenetic characterisation of an imported case of SARS-CoV-2 in Amazonas State, Brazil. Mem Inst Oswaldo Cruz. 2020 Epub Sep 25. doi: https://doi.org/10.1590/0074-02760200310
Nicola M, O’Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence Based Management Guideline for the COVID-19 Pandemic – review article. Int J Surg. 2020;S1743-9191(20):30284-3. doi: https://doi.org/10.1016/j.ijsu.2020.04.001
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: https://doi.org/10.1016/j.ijantimicag.2020.105924
Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608-21. doi: https://doi.org/10.1093/jac/dkv018
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16; 14(1):72-73. doi: https://doi.org/10.5582/bst.2020.01047
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: https://doi.org/10.1016/j.ijantimicag.2020.105949
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. doi: https://doi.org/10.1038/s41422-020-0282-0
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279-283. doi: https://doi.org/10.1016/j.jcrc.2020.03.005
Jeevaratnam K. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):256-257. doi: https://doi.org/10.1093/ehjcvp/pvaa041
Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19-27. doi: https://doi.org/10.1016/j.cmi.2020.08.022
Bignardi PR, Vengrus CS, Aquino BM, Cerci Neto A. Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. Pathog Glob Health. 2021;115(3):139-150. doi: https://doi.org/10.1080/20477724.2021.1884807
Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, Laksman Z, Healey JS, Krahn AD. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020;36(6):948-951. doi: https://doi.org/10.1016/j.cjca.2020.04.003
Nicola M, O’Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based management guideline for the COVID-19 pandemic - Review article. Int J Surg. 2020;77:206-216. doi: https://doi.org/10.1016/j.ijsu.2020.04.001
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. doi: https://doi.org/10.1111/jth.14768
Jhaveri KD, Meir LR, Flores Chang BS, Parikh R, Wanchoo R, Barilla-LaBarca ML, Bijol V, Hajizadeh N. Thrombotic microangiopathy in a patient with COVID-19. Kidney Int. 2020;98(2):509-512. doi: https://doi.org/10.1016/j.kint.2020.05.025
Eliquis® (apixaban) - Recommendations to reduce the risk of bleeding associated with treatment with apixaban. Laboratorios Pfizer Ltda, April 23; 2019. Available from: http://portal.anvisa.gov.br/documents/33868/5270120
Mandernach MW, Beyth RJ, Rajasekhar A. Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review. Ther Clin Risk Manag. 2015;11:1273-82. doi: https://doi.org/10.2147/TCRM.S68010
Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH; ARISTOTLE Investigators. Clinical and pharmacological effects of Apixaban dose adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020;75(10):1145-1155. doi: https://doi.org/10.1016/j.jacc.2019.12.060
Ministry of Health, Secretariat of Science and Technology, General coordination of health technology management, Coordination of management of Clinical Protocols and Therapeutic Guidelines. Guidelines for the diagnosis and treatment of COVID-19. Accessed on 02/12/2020 at 09:00.
Rockwell KL, Gilroy AS. Incorporating telemedicine as part of COVID-19 outbreak response systems. Am J Manag Care. 2020;26(4):147-148. doi: https://doi.org/10.37765/ajmc.2020.42784
Sanei Taheri M, Falahati F, Radpour A, Karimi V, Sedaghat A, Karimi MA. Role of Social Media and Telemedicine in Diagnosis & Management of COVID-19; an Experience of the Iranian Society of Radiology. Arch Iran Med. 2020;23(4):285-286. doi: https://doi.org/10.34172/aim.2020.15
Moher D, Schulz KF, Altman D; CONSORT Group. Consolidated Standards of Reporting Trials. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285(15):1987-91. doi: 10.1186/1471-2288-1-2
Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19-27. doi: https://doi.org/10.1016/j.cmi.2020.08.022
Godino C, Scotti A, Maugeri N, Mancini N, Fominskiy E, Margonato A, Landoni G. Antithrombotic therapy in patients with COVID-19? Rationale and Evidence. Int J Cardiol. 2021;324:261-266. doi: https://doi.org/10.1016/j.ijcard.2020.09.064.
Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, Wurtz N, Rolain JM, Colson P, La Scola B, Raoult D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228. doi: https://doi.org/10.1016/j.micpath.2020.104228
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: a randomized trial. Ann Intern Med. 2020;173(8):623-631. Erratum in: Ann Intern Med. 2021;174(3):435. doi: https://doi.org/10.7326/M20-4207
Carvalho CRR, Scudeller PG, Rabello G, Gutierrez MA, Jatene FB. Use of telemedicine to combat the COVID-19 pandemic in Brazil. Clinics (Sao Paulo). 2020;75:e2217. doi: https://doi.org/10.6061/clinics/2020/e2217
Vidal-Alaball J, Acosta-Roja R, Pastor Hernández N, Sanchez Luque U, Morrison D, Narejos Pérez S, Perez-Llano J, Salvador Vèrges A, López Seguí F. Telemedicine in the face of the COVID-19 pandemic. Aten Primaria. 2020;52(6):418-422. doi: https://doi.org/10.1016/j.aprim.2020.04.003
Brasil. Ministério da Saúde. Secretaria de Atenção Primária à Saúde (SAPS). Protocolo de manejo do coronavirus (COVID-19) na Atenção Primária à Saúde. Brasília, DF; maio 2020 [citado 03 jul. 2020]. Disponível em: https://www.unasus.gov.br/especial/covid19/pdf/37
Recovery Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-2040. doi: https://doi.org/10.1056/NEJMoa2022926
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020:1-8. doi: https://doi.org/10.1007/s42399-020-00363-4
Deng J, Zhou F, Hou W, Silver Z, Wong CY, Chang O, Huang E, Zuo QK. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021;1486(1):90-111. doi: https://doi.org/10.1111/nyas.14506
Buchberger AMS, Baumann A, Johnson F, Peters N, Piontek G, Storck K, Pickhard A. The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol. 2018;275(8):2035-2043. doi: https://doi.org/10.1007/s00405-018-5043-z
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Matheus Henrique Fernandes, Matheus Rodrigues de Oliveira, Alfredo Herbert Zielke Filho, Clóvis José Torres Gomes, Lucyara Martins Oliveira, Frederico Palumbo Araújo, Sofia Mirela Schreier Rodrigues, Karine Paiva de Andrade, Ana Clara Beraldo Muniz, Gabriel Prado Leão Teixeira, Guilherme Tadeu Tucci Castilho Junior, Mariana Gazzinelli Maiolini, Camilla Kallás Hueb, Elisa Rosa Silva, Paula Fernanda Correa, Marcella Nora Maia, Maria Eugênia Sousa Magalhães, Laís Boczar Dias, Pedro Augusto Schreier Rodrigues, José Renato de Melo, Breno César Diniz Pontes, Paulo Roberto Maia, Sérgio Rodrigo Beraldo, José Dias da Silva Neto
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
